Post-exposure prophylaxis (PEP) involves taking antiretroviral drugs after potential exposure to HIV to prevent infection. Studies show a transmission rate of 0.33% from needlesticks and 0.09% from mucosal exposures to HIV-infected sources. Nurses and lab technicians made up most occupational transmissions. PEP drug regimens use 2-3 antiretrovirals started within 24 hours for 4 weeks. While animal studies show high protection when started early, human cases still seroconvert, indicating efficacy below 100%. Timing and duration of PEP are based on CDC and WHO guidelines.
PEP is a medical response given to prevent the transmission of pathogens after potential exposure.
PEP for HIV refers to a set of comprehensive services to prevent HIV infection in exposed individuals.
These services include, first aid care, counselling and risk assessment, HIV testing based
on informed consent, and depending on risk assessment, the provision of short term (28 days)antiretroviral (ARV) drugs, with follow up and support.
PEP is a medical response given to prevent the transmission of pathogens after potential exposure.
PEP for HIV refers to a set of comprehensive services to prevent HIV infection in exposed individuals.
These services include, first aid care, counselling and risk assessment, HIV testing based
on informed consent, and depending on risk assessment, the provision of short term (28 days)antiretroviral (ARV) drugs, with follow up and support.
Are you injured by used needle ? You may be at risk of getting blood born pathogen like HIV, Hepatitis B and Hepatitis C. Good news is that still you have chance of protect yourself from potential HIV and Hepatis B infection by using post exposure prophylaxis.
Presentation by Dr. Arthur Dessi Roman discussing the importance of safe injection practices and revisiting the recommendations on sharp injury prevention technologies
Post exposure prophylaxis- HEALTH SECTOR WELLNESS SERVICES SEJOJO PHAAROE
HIV and HIV transmission
Indicators for PEP
Pre—requisite for PEP
-baseline and follow up tests
Pre-requisite for PEP Provision
PEP package
ARV- Treatment and adherence
Sharp injuries and needle stick post exposure prophylaxis [compatibility mode]drnahla
Infection Control Guidelines for Sharp injuries and needle stick post exposure prophylaxis
Dr. NAHLA ABDEL KADERوMD, PhD.
INFECTION CONTROL CONSULTANT, MOH
INFECTION CONTROL CBAHI SURVEYOR
Infection Control Director, KKH.
This presentation on how dried blood spot testing may overcome some of the barriers to HIV testing was given by Philip Cunningham, NSW State Reference Laboratory for HIV, at the AFAO Members Forum - May 2015.
This bulletin is a publication of the CRC networks in Perak (Hospital Raja Permaisuri Bainun Ipoh, Hospital Seri Manjung and Hospital Taiping).
This issue emcompasses various research articles written by CRC staff, a research scope write-up to emphasize on the research focus this coming year, programmes conducted in 2021 as well as upcoming events across the CRC Perak Network this year.
(e-ISSN Number: 2682-7867).
Philadelphia FIGHT's PrEP Retention and Adherence Coordinator Devon Clark presented on HIV Pre-exposure Prophylaxis (PrEP) at the September 2016 meeting of the Positive Committee.
Role of Personal Protective Measures in Prevention of COVID-19 Spread Among P...NurFathihaTahiatSeeu
Research Paper review on: Role of Personal Protective Measures in Prevention of COVID-19 Spread Among Physicians in Bangladesh
Here, we reviewed the strength, weaknesses, methodology, results and other important things this research paper showed.
Triple combination of
interferon beta-1b, lopinavir – ritonavir, and ribavirin
in the treatment of patients admitted to hospital with COVID-19:
an open-label, randomized, phase 2 trial
Are you injured by used needle ? You may be at risk of getting blood born pathogen like HIV, Hepatitis B and Hepatitis C. Good news is that still you have chance of protect yourself from potential HIV and Hepatis B infection by using post exposure prophylaxis.
Presentation by Dr. Arthur Dessi Roman discussing the importance of safe injection practices and revisiting the recommendations on sharp injury prevention technologies
Post exposure prophylaxis- HEALTH SECTOR WELLNESS SERVICES SEJOJO PHAAROE
HIV and HIV transmission
Indicators for PEP
Pre—requisite for PEP
-baseline and follow up tests
Pre-requisite for PEP Provision
PEP package
ARV- Treatment and adherence
Sharp injuries and needle stick post exposure prophylaxis [compatibility mode]drnahla
Infection Control Guidelines for Sharp injuries and needle stick post exposure prophylaxis
Dr. NAHLA ABDEL KADERوMD, PhD.
INFECTION CONTROL CONSULTANT, MOH
INFECTION CONTROL CBAHI SURVEYOR
Infection Control Director, KKH.
This presentation on how dried blood spot testing may overcome some of the barriers to HIV testing was given by Philip Cunningham, NSW State Reference Laboratory for HIV, at the AFAO Members Forum - May 2015.
This bulletin is a publication of the CRC networks in Perak (Hospital Raja Permaisuri Bainun Ipoh, Hospital Seri Manjung and Hospital Taiping).
This issue emcompasses various research articles written by CRC staff, a research scope write-up to emphasize on the research focus this coming year, programmes conducted in 2021 as well as upcoming events across the CRC Perak Network this year.
(e-ISSN Number: 2682-7867).
Philadelphia FIGHT's PrEP Retention and Adherence Coordinator Devon Clark presented on HIV Pre-exposure Prophylaxis (PrEP) at the September 2016 meeting of the Positive Committee.
Role of Personal Protective Measures in Prevention of COVID-19 Spread Among P...NurFathihaTahiatSeeu
Research Paper review on: Role of Personal Protective Measures in Prevention of COVID-19 Spread Among Physicians in Bangladesh
Here, we reviewed the strength, weaknesses, methodology, results and other important things this research paper showed.
Triple combination of
interferon beta-1b, lopinavir – ritonavir, and ribavirin
in the treatment of patients admitted to hospital with COVID-19:
an open-label, randomized, phase 2 trial
Dr. Kurt Stevenson - An Overview of Antimicrobial UseJohn Blue
An Overview of Antimicrobial Use - Dr. Kurt Stevenson, The Ohio State University Medical Center, from the 2012 NIAA One Health Approach to Antimicrobial Resistance and Use Symposium, November 13-15, 2012, Columbus, OH, USA.
More presentations at:
http://www.trufflemedia.com/agmedia/conference/2012-one-health-to-approach-antimicrobial-resistance-and-use
Dr. Kurt Stevenson - An Overview of Antimicrobial UseJohn Blue
An Overview of Antimicrobial Use - Dr. Kurt Stevenson, The Ohio State University Medical Center, from the 2012 NIAA One Health Approach to Antimicrobial Resistance and Use Symposium, October 26-27, 2012, Columbus, OH, USA.
More presentations at:
http://www.trufflemedia.com/agmedia/conference/2012-one-health-to-approach-antimicrobial-resistance-and-use
Charles Feldman is Professor of Pulmonology and Chief Physician at Charlotte Maxeke Johannesburg Academic Hospital. In this talk given at an ICN Victoria meeting last year, he discusses the alphabet soup that represent pneumonia phenotypes and clarifies what it's all about. His unique perspective on the history behind this incredible relevant topic is well worth hearing and hopefully clarifies some misconceptions.
MANAGEMENT OF COMPLICATIONS AFTER LRP: HOW TO IMPROVE EARLY CONTINENCE AND MA...Eduard Garcia Cruz
Mi presentación en las jornadas "MINIMALLY INVASIVE PROSTATE SURGERY" en Oporto del 24 y 25 de enero del 2014 - "Gestión de las complicaciones después de la prostatectomía radical laparoscópica (PRL): Cómo mejorar la incontinencia temprana y gestionar la disfunción eréctil".
3. Risk of transmission A total of 23 studies of needle sticks among healthcare workers demonstrate HIV transmission in 20 of 6135 (0.33%) exposed to an HIV infected source.( Ann of Intern Med 1990;113;740) with mucosal surface exposure there was one transmission in 1143 exposures (0.09%) and there was no transmission in 2712 skin exposures.
4. Risk of viral transmission with sharps injury from infected source 2003 Johns Hopkins HIV guide
5. Of 56 confirmed HIV transmission in the occupational setting in USA Nurses 23 Lab Techs 20 Physicians 6 Type of exposure Percutaneous 48 Mucocutaneous 5 Both 2MMWR June 29, 2001 / 50(RR11);1-42
7. Drugs used for PEP 2 drug combinations Zidovudine + Lamivudine Lamivudine + Stavudine Stavudine + didanosine 3 Drug combination Above list + indinavir, nelfinavir, efavirenz, abacavir, ritonavir or lopinavir/ ritonavirMMWR June 29, 2001:50(RR11);1-42
8. Expanded regimens for PEP if source patient is already receiving ART the drug regimen for PEP will depend on what drugs the source patient is taking and the possibility of drug resistance in the source.MMWR June 29, 2001:50(RR11);1-42
9. Evidence of Efficacy of PEP animal models: high level of protection when started within 24 hours1 79% reduction of transmission with zidovudine use in case-control study2 two drugs, three drugs: no direct evidence that more effective than 1 drug cases of seroconversion despite 3-drug PEP imply efficacy less than 100%3,4 1. Tsai C-C et al. J Virol 1998;72:4265-73. 2. Cardo DM et al. NEJM 1997;337:1485-90. 3. Jochinsen EM et al. Arch Int Med 1999;159:2361-3. 4. MMWR June 29, 2001 / 50(RR11);1-42
11. Duration of PEP 4 weeks (28 days) used in case-control study2 and recommended by CDC / WHO guidelines3 1. Tsai C-C et al. J Virol 1998;72:4265-73. 2. Cardo DM et al. NEJM 1997;337:1485-90. 3. MMWR June 29, 2001:50(RR11);1-42.